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PENGHASILAN DAN PENILAIAN SINGLE-CHAIN VARIABLE 
FRAGMENT (scFv) INTRABODI YANG BERFUNGSI TERHADAP 





HIV/AIDS adalah wabak yang menyerang di seluruh dunia. Walaupun 
kemajuan dalam rawatan HIV telah mengurangkan perkembangan penyakit ini, 
namun penyakit lain yang dikaitkan dengan AIDS dan kadar kematian masih kekal 
tinggi. Ini disebabkan oleh kelemahan dalam pelaksanaan rawatan dan kemunculan 
baka HIV yang mempunyai daya tahan terhadap ubat yang sedia ada. Oleh itu, 
terdapat keperluan yang berterusan untuk meneroka pendekatan baru bagi 
membangunkan kaedah rawatan alternatif terhadap HIV/AIDS. Kapsid protein HIV, 
p24 membentuk teras konikal yang meliputi genom virus dan memainkan peranan 
yang penting dalam peringkat awal dan akhir kitaran hidup virus. Sebagai sasaran 
terapeutik yang berpotensi, protein p24 telah menarik perhatian yang agak besar 
sejak beberapa tahun kebelakangan ini. Penemuan penting yang memperlihatkan 
faktor-faktor sekatan perumah seperti Trim5α dan Mx2 yang menyasarkan teras 
konikal p24 memperlihatkan potensi p24 sebagai sasaran pencegahan terhadap virus 
HIV. Kajian sedia ada bertujuan untuk menghasilkan antibodi single chain variable 
fragment (scFv) yang khusus terhadap protein p24 HIV-1 dan menilai aktivitinya 
sebagai intrabodi. Urutan pengekodan rantaian ringan (VL) dan rantaian berat (VH) 
pada bahagian boleh ubah yang diklon dari cDNA sel hybridoma (klon 183-H12-5C) 
menghasilkan antibodi terhadap p24 HIV. Urutan VH dan VL telah dihubungkan 
dengan satu turutan pengikat peptide yang fleksibel dan diekpres sebagai scFv. scFv 
anti-p24 yang terhasil berinteraksi secara khusus dengan p24 dari virus dan p24 
xxiii 
 
rekombinan dan menghalang penggabungan p24 di dalam ekperimen tabung uji. 
Apabila diekspresikan di dalam sel, scFv anti-p24 secara ketara menghalang replikasi 
virus di dalam sel MAGI, sel Jurkat T, dan PBMC. Kesimpulannya, scFv anti-p24 
antibodi yang dihasilkan dalam kajian ini boleh digunapakai sebagai medium yang 
berharga bagi membangunkan kaedah bio-terapeutik berasaskan antibodi yang 
berupaya menentang HIV/AIDS. 
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GENERATION AND EVALUATION OF A FUNCTIONAL SINGLE-CHAIN 






HIV/AIDS is now present in every country in the world. Although advances 
in the treatment of HIV have reduced the progress of the disease, AIDS related 
illnesses and deaths remain high due to poor compliance with treatment and 
emergence of drug -resistant HIV strains. Thus there is a persistent need to explore 
new approaches for developing alternative treatment modalities against HIV/AIDS. 
The HIV capsid protein p24 forms the conical core that encapsulates the viral 
genome inside the virus and plays crucial roles in both early and late stages of viral 
life cycle. As a potential therapeutic target, the p24 protein has attracted considerable 
attention in recent years. Key findings that host restriction factors such as Trim5α 
and Mx2 target incoming conical core accentuate the potential of p24 as a feasible 
anti-HIV target. The aim of the present study was to generate a single chain variable 
fragment (scFv) antibody specific to HIV-1 p24 protein and evaluate its anti-HIV 
activity as intrabody. Sequences encoding variable regions of heavy (VH) and light 
(VL) chains were cloned from cDNA isolated from a hybridoma cell line producing 
HIV p24 mAb (clone 183-H12-5C). The VH and VL sequences were linked by a 
flexible peptide linker sequence and expressed as scFv. The resulting anti-p24 scFvs 
interacted specifically with both recombinant and virus -derived p24 and inhibited 
p24 polymerisation in an in vitro assay. Intracellularly expressed anti-p24 scFv 
markedly inhibited viral replication in CD4/CCR5 -expressing MAGI, Jurkat T cells, 
and PBMCs. In conclusion, anti-p24 scFv antibody generated in this work may serve 
xxv 
 





CHAPTER 1: INTRODUCTION 
1.1 AIDS Epidemic 
Acquired immunodeficiency syndrome (AIDS) is one of the biggest threats to human 
health around the world since it’s discovery in 1981 (Centers for Disease Control 
(CDC) 1981). In 1983, the human immunodeficiency virus (HIV) had been identified 
as the leading cause of AIDS (Barré-Sinoussi et al. 1983; Gallo et al. 1983). Two 
viruses being detected liable for the development of AIDS in humans are HIV-1 and 
HIV-2 which represent multiple independent zoonotic transmission of simian 
immunodeficiency virus (SIV). HIV-1 was passed into a human through chimpanzee 
virus (SIVcpz), while HIV-2 was transferred from Sooty mangabeys (Cohen et al. 
2008; Sharp & Hahn 2011). In the deficiency of precautionary vaccines, the viruses 
remain a human pathogen that threatens people's health for the coming decades. 
Ongoing efforts in designing and developing anti-HIV-1 drugs and vaccines have 
proven to be insufficient for eradicating or averting HIV/AIDS (Ensoli et al. 2014). 
The HIV pandemic documents that approximately 36.7 million people infected by 
HIV-1 globally (UNAIDS 2015). An estimated 1-2 million infections caused by 
HIV-2 in Africa and India regions which most of the patient progresses more slowly 
(Ingole et al. 2013; de Silva & Weiss 2010; Campbell-Yesufu & Gandhi 2011). 
Developing countries show high cases of AIDS -related illnesses and deaths yearly. 
As evident, Malaysia has shown a stabilised HIV/AIDS cases over last five years. 
Since 2002 average of 9 new cases of HIV/AIDS was reported each day (Shitan & 
Mondal 2011; HIV/STI Section MOH Malaysia 2011; HIV/STI Section Ministry of 
Health Malaysia 2015) 
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Once infections take place (Figure 1.1), human can harbour the virus for a decade or 
more without showing clear clinical appearances (Buchbinder et al. 1994; Learmont 
et al. 1992). As presented in Figure 1.2, in the lack of treatment, ultimately, the virus 
replication reduces the circulating CD4+ T cells below 200 cells per cm3. In contrast, 
an average of 800 cells per cm3 is detected for healthy people thus suggesting the 
depletion of severe immune cells for people that progressed HIV-1/AIDS  (Shete et 
al. 2010; Rodger et al. 2011). This observation promotes to an extensive series of 
AIDS –related illness (Ledergerber et al. 1999; Bakshi 2004). Indeed, HIV-1 infected 
CD4+T can produce up to 10x109 virions per day in an infected person and having a 
half-life of 2.2 days (Perelson et al. 1996). 
Implementation of antiretroviral therapy (ART) prolongs life likelihood of 
individuals who newly diagnosed with AIDS. ART is still the best available 
treatment for managing HIV/AIDS. A significant effect of drug combinations in the 
treatment had improved the prognosis of HIV-1 patients which lead to less 
transmission of the virus to the environment (Bartlett et al. 2001; Bartlett et al. 2006; 
Egger et al. 2002). Table 1.1 showed FDA approval drugs and the combinations 
using in ART. It is successful to constrain the pandemic and lowers the mortality. 
However, drug-resistant HIV-1 strains still can cause the increment of the death rate 
(Emamzadeh-Fard et al. 2013). Thus, the exploration of new approaches is needed in 





Figure 1.1 HIV transmission and early immunological events. Obtained from 
(Rodger et al. 2011) 
 
Figure 1.2 Natural history of HIV infection in: (A) untreated progressors; (B) 




Table 1.1 List of FDA-approved anti-HIV drugs. Drugs used in anti-retroviral 








Table 1.1. Continued 
 
 




1.2 HIV-1 Structure and Genome Organisation 
HIV type 1 (HIV-1) is categorised under the human lentivirus genus in retroviridae 
family (Cullen 1991; Rodger et al. 2011). The size of HIV-1 virus ranged between 
119 to 207 nm with average diameter of 145 nm (Briggs et al. 2004; Briggs et al. 
2003). The ~9.8 kb HIV-1 provirus comprise of the genes that encode at least nine 
proteins which can be divided into three classes: 1) The structural protein; 2) The 
regulatory protein; 3) The accessory protein (Frankel & Young 1998; Bruggeman et 
al. 1994). The ~9.2 kb primary transcript (HIV-1 mRNAs unspliced) is a homodimer 
of linear, positive-sense, and single-stranded RNA which generated from the 
expression of 5’ LTR to 3’ LTR (Moore & Hu 2009; Bohne et al. 2005). It is 
necessary for the production of mature infectious HIV-1 viruses (Karn & Stoltzfus 
2012). Besides, the distribution of Gag and Gag-Pol protein at a ratio of 20:1 in 
virus-producing cells is also critical for viral infectivity (Shehu-Xhilaga & Crowe 
2001; Sundquist & Krausslich 2012). 
The Gag, Pol, and Env proteins are the major proteins that are common to all 
retroviruses (Katz & Skalka 1994; Wills & Craven 1991). In order to form the core 
structure of HIV-1 virion, the HIV-1 Gag polyprotein undergoes the proteolytic 
processing by the viral protease (PR) that generates matrix (MA; p17), capsid (CA; 
p24), nucleocapsid (NC; p7) and p6 (Ganser-Pornillos et al. 2012). The formation of 
HIV-1 viral envelope is driven by the cleavage of HIV-1 Env precursors (gp160) by 
the cellular protease furin in the Golgi that produces surface (SU; gp120) and 
transmembrane (TM; gp41) (Freed 2013). The enzymes that necessarily involve in 
HIV-1 replication are generated from the proteolytic process of HIV-1 Gag-Pol 
polyprotein by the viral PR. They are protease (PR), reverse transcriptase (RT), and 
integrase (IN) (Konnyu et al. 2013). HIV-1 also encodes two regulatory proteins 
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such Tat and Rev together with four accessory proteins like Vif, Vpr, Nef and Vpu 
which facilitate in the enhancing of viral infectivity, regulatory functions, and proper 
viral assembly (Frankel & Young 1998).  Figure 1.3 shows the structure and genome 





Figure 1.3 HIV-1 structure and genome. A. Cross section of the HIV-1 virion. 
B. HIV-1 genome is encoding the nine viral proteins and six accessory proteins. 
Modified from (Frankel & Young 1998) 
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1.3 HIV-1 Virus Replication Cycle 
The HIV replication begins with a series of events that can be categorised in two 
phases which are known as early and late. The early phase starts when the mature 
viruses recognise the target cells until the genomic DNA integrates into the 
chromosome of the host cell. Meanwhile, the late phase starts when integrated 
proviral genome is regulated until the virus reaches the maturation stage (Figure 1.4). 
1.3.1 Early Phase 
HIV-1 attachment (step 1) is mediated via the binding of the surface envelope 
glycoprotein gp120 to the primary host receptor CD4 (Mondor et al. 1998; Wilen et 
al. 2012) followed by the binding to the chemokine receptors either CCR5 or 
CXCR4. R5- and X4-tropic HIV-1 isolates utilise CCR5 or CXCR4, respectively, as 
a co-receptor (Collman et al. 2000; Xiang et al. 2010). Dual-tropic HIV-1 can use 
either CXCR4 or CCR5 as co-receptor (Yi et al. 1999; Xiang et al. 2011; Yi et al. 
2005). Once HIV-1 binds CD4 and co-receptor on the cell surface, its triggering 
conformational changes in the transmembrane Env glycoprotein gp41 that promote 
fusion of the viral and cellular membranes (step 2) (Pancera et al. 2010). Fusion 
process releases the viral capsid core and leads the entry into the cytoplasm of the 
target cell where HIV-1 undergoes a series of complex viral core uncoating steps. 
Several findings proposed that the capsid core remains intact post-entry rather than 
fully disassembled, to an undetermined extent, until the core docks with the nuclear 
pore to release the pre-integration complex (step 3) (Wilen et al. 2012; Blumenthal et 
al. 2012; Ambrose & Aiken 2014; Nathalie Arhel 2010). The newly formed pre-
integration complex, composed of viral RNA, MA, Vpr, and IN, is transported across 
the nuclear envelope (step 4) (Popov et al. 1998; Piller et al. 2003; Tsurutani et al. 
2007). Viral RNA is then reverse transcribed into double stranded DNA by the viral 
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enzyme RT (step 5) (Ben-Artzi et al. 1992; Hu & Hughes 2012). Once completely 
reverse transcribed, the proviral DNA is integrated into the host cellular genome 
using HIV-1 IN (step 6) (Butler et al. 2001; Craigie & Bushman 2012). 
1.3.2 Late Phase 
Viral RNA expression is regulated from the HIV-1 long terminal repeat (LTR) 
promoter and viral and cellular proteins (step 7) (Karn & Stoltzfus 2012). Viral 
proteins and RNA undergo assembly (step 8) into immature viral particles that bud 
from the cell surface (step 9) (Sundquist & Krausslich 2012; Freed 2015). The 55-
kDa Gag polyprotein is the protein that mediates the assembly and budding of the 
immature virion. Once released, proteolytic processing via the viral enzyme PR 
promotes virus maturation (step 10), which is necessary to create an infectious virion 
(Konvalinka et al. 2015). Since capsid and capsid core involve in both phases of 
HIV-1 replication, targeting the p24 protein is a viable option for developing 
































Early phase Late phaseA. B.
C. D.
 
Figure 1.4 HIV-1 life cycle. A. Early phase. B. Late phase. C. Central section 
from a cryo-EM tomographic reconstruction of an immature HIV-1 virion D. Central 
section from a tomographic reconstruction of a mature HIV-1 virion. Image C and D 
obtained from (Sundquist & Krausslich 2012) 
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1.4 HIV-1 Capsid protein 
1.4.1 HIV-1 Capsid p24 Structure 
HIV-1 CA p24 comprises of a 231 amino-acid protein encoded by HIV-1 gag gene. 
N-terminal domain (NTD) and C-terminal domain (CTD) are two different domains 
of HIV-1 CA p24 that connected by a flexible 5-amino acid peptide linker (146-150) 
(Jiang et al. 2013; Arvidson et al. 2003). The NTD (aa 1-145) contains seven helices 
(numbered 1–7) and one amino-terminal hairpin that is thought to be involved in the 
virus infectivity (Morikawa et al. 2000). The C-terminal domain (aa 146–231) 
comprises of four short helices (numbered 8–11) and a single-turn 310-helix that 
might contribute to the assembly process during the late stage of virus replication 
(Ternois et al. 2005).  
The NTD is apparently forming the hexamers while the CTD is forming dimeric 
linkers that connect neighboring hexamers. The presence of NTD-CTD interactions 
identified from biochemical and genetic experiments suggest that the interaction is 
essential for hexameric CA p24 formation (Ganser-Pornillos et al. 2007)(Figure 
1.5B). Cyclophilin A (CypA) binds CA p24 on residues 85–93 between helices 4 and 
5 that is exposed at the surface of the hexameric CA (Gamble et al. 1996; Luban 
1996) (Figure 1.5A). The p24 protein of mature virus forms the fullerene conical 
structure that encapsulates the genomic RNA-nucleocapsid complex (Erdemci-
Tandogan et al. 2016). The core with an average size of 100–120 nm in length and 
50–60 nm in wide possessed of approximately 250 CA hexameric rings which form 
lattice structure (Briggs et al. 2003)(Figure 1.5C). The hexameric lattice comprises of 
about 1,000–1,500 assembled CA p24 proteins with a 10 nm spacing (Briggs et al. 
2004)(Figure 1.5D). Both canonical CA p24 structural domains have shown to be 






Figure 1.5 Structure of the CA protein, HIV-1 core, and the CA hexameric 
lattice. (A) Side view of the pseudoatomic monomer model of full-length CA, with 
the secondary structural elements, labeled, including the cypA-binding loop. Yellow 
asterisks indicate the carboxy terminus of the NTD and the amino terminus of the 
CTD (approximately 4 ˚A apart). (B) Polar and water-mediated intermolecular CA 
contacts within a hexamer. (C) Stereo view of a backbone-only fullerene cone model 
composed of 1056 CA subunits. (D) Top view of one sheet in the templated CA 
crystals, which recapitulates the hexameric lattice of authentic capsids at its planar 
limit. The NTDs are colored orange, and the CTDs are blue. Interactions between 
neighboring hexamers are mediated only by the CTD. Right-hand box, a top view of 
the CTD–CTD interface that connects adjacent hexamers. The black oval represents 
the twofold symmetry axis. Obtained from (Fassati 2012) 
 15 
 
1.5 HIV-1 Capsid p24 Inhibitor 
1.5.1 Innate immune response factors 
1.5.1(a) TRIM5α 
The species-specific retroviral restriction factor, the coiled-coil domain  TRIM5, and 
the related protein TRIMCyp, which are a part of the innate immune response factors 
have been revealed to react with incoming core CA p24 and evade infection of HIV-
1 (Matthew et al. 2004; Sayah et al. 2004; Neagu et al. 2009). The binding expedites 
the uncoating process, hypothetically as a result of TRIM5 assembling on top of the 
hexameric CA lattice (Stremlau et al. 2006; Owen Pornillos, Barbie K. Ganser-
Pornillos 2011). However, the human TRIM5 demonstrated less efficient in 
inhibition of HIV-1 compared to rhesus monkey TRIM5. Removal of arginine 332 in 
the human TRIM5 domain and replaced with proline which is residue find in rhesus 
monkey TRIM5 showed a potent inhibition of both HIV-1 and SIV replication (Li et 
al. 2006; Javanbakht et al. 2006) 
1.5.1(b) Mx2 
Human myxovirus resistance 2 (Mx2 or MxB) is a group of the IFN-inducible 
GTPase superfamily, comprises of the proteins that functioning in cellular processes 
like cytokinesis, vesicular transport, and blocking of the intracellular pathogens (Liu 
et al. 2013; Goujon et al. 2013). The protein shows potent activity against primate 
immunodeficiency virus HIV-1 and does not affect the non-primate viruses such as 
EIAV, MLV, and FIV. Downregulation of the protein by RNA interference 
decreased the anti-HIV-1 potency of IFNα (Kane et al. 2013). Mx2 reduces the 2-
LTR circles levels and proviruses by ~90%. These findings supporting that Mx2 
prevent the HIV-1 nuclear import and DNA integration. Mx2 also increases the 




Coiled-coil domain containing protein 8 (CCDC8) is a human membrane-associated 
protein that showed to inhibit the HIV-1 particle production. The protein mainly acts 
by binding towards Gag matrix region on the plasma membrane and was detected in 
virion of HIV-1. The interaction of Gag and CCDC8 led to Gag polyubiquitination 
and endocytosis degradation (Wei et al. 2015). 
1.5.2 Capsid-based assembly inhibitor 
Currently, small molecule inhibitors representing either natural compounds or 
synthetic peptides are being tested for their antiviral activity against HIV-1 CA p24. 
The most important compound is CAP-1 that had been identified by Tang and group 
in 2003 (Tang et al. 2003). Study on CAP-1 by different groups resulted in 
understanding the mechanism of viral inhibition by specifically targeting HIV-1 CA 
p24 (Kelly et al. 2007). Almost a decade of its finding, the binding pocket of the 
amino-terminal domain of CA (NTD CA)/CAP-1 has been used in high-throughput 
screening of the potential anti-HIV compounds. Although the pocket model 
successfully identified the potential compounds, most of them were inactive in in 
vivo assessment. Lately, the trend in the identification of the potential compound has 
carried out by a combination of both approaches. This strategy led to identifying the 
compound such acylhydrazone, benzodiazepine, benzimidazole, PF-3450074, I-XW-
053, H22, and pyrrole pyrazolones that act against HIV CA p24.  
Meanwhile, the most known synthetic peptide is CAI that had been published by 
Sticht et al. (2005) three years after CAP-1. The 12-mer α-helical peptide was 
successfully identified by phage display technology that binds the carboxyl-terminal 
domain of CA (CTD CA). The binding led to the assembly inhibition of immature- 
and mature-like capsid particles in vitro (Sticht et al. 2005). A few years later, 
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several studies had shown the improvements of the peptide. Hydrocarbon stapling 
technique that stabilises the α-helical structure of CAI resulted in the conversion of 
the peptide into a cell-penetrating peptide (CPP). This modified peptide called as 
NYAD was found to increase the cell permeability which ultimately led to the 
inhibition of HIV replication. Series of studies by Zhang et al. (2008) concluded that 
the peptide bind to CTD of CA at post-entry of HIV replication (Zhang et al. 2008; 
Zhang et al. 2011; Zhang et al. 2013). In the meantime, a less known peptide that 
was identified almost at the same time with CAP-1 is CAC1. The 20-mer synthetic 
peptide showed binding against the carboxyl-terminal domain of CA (CTD CA) in 
vitro setting (Garzón et al. 2004). Same as CAI, the CAC1 was unable to penetrate 
the cell membrane and needed the cell penetrating peptide to cross the cells. CAC1M 
was shown to inhibit CA polymerisation in vitro and the combination of CAC1M 
with established peptides such CAC1, and H8 resulted in 90% inhibition of HIV 
particle production (Bocanegra et al. 2011).  
Like most of the small inhibitors and peptide inhibitors are targeting the NTD of CA 
and CTD of CA respectively, recent finding showed the inhibitors like quinolinone, 
phenyl, Ebselen, and 2-Arylquinazolines also could bind to CTD of CA (Curreli et 
al. 2011; Thenin-Houssier et al. 2016; Machara et al. 2016).  
Figure 1.6 shows the capsid inhibitors against HIV-1 CA p24 and next sections are a 





Figure 1.6 HIV-1 capsid p24 inhibitors. A. Capsid-based post-entry inhibitors. 
B. Capsid-based assembly inhibitors. C. Capsid-based maturation inhibitors.  
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1.5.2(a) Small molecule 
1.5.2(a)(i) CAP-1 
As mentioned before, CA p24 is involved in both phases in HIV replication. At the 
early stage of HIV replication, the HIV-1 Gag polyprotein will assemble and start to 
form a budding at the membrane of cells. Disruption or destabilising of this process 
is believed to block the virus production or lead to the production of non-infectious 
viruses.  More than a decade researchers found that there were inhibitors that 
responsible for this process and some of them classified these inhibitors as capsid-
based assembly inhibitor. The discovery of the earliest inhibitors in the series was 
CAP-1. Summers and the group had found this small molecule by computationally 
screening based on docking technique (AUTODOCK4.0). The molecule binds to the 
amino-terminal domain (NTD) of the immature capsid between helices 1 and 2, in 
residue 59-63 during the early step in HIV replication verified by NMR titration 
assay (Kelly et al. 2007). 
The compound was found to decrease the rate of the p24 assembly during in vitro 
CA p24 assembly and inhibited viral infectivity up to 95% and 98% in latently 
infected U1 cells and MAGI cells, respectively. Interestingly, the high or low 
concentration of CAP-1 had no effect on HIV particle production and Gag 
expression. Morphology analysis of the virions produced from CAP-1-treated cells 
by an electron microscope showed the presence of greater size heterogeneity virions 
with most of them do not have a cone-shaped core. These observations suggest that 
the molecule interacted with HIV CA p24 of immature HIV at the late phase HIV 
replication that led to Gag assembly defect and subsequently production of less 
infectious viruses (Tang et al. 2003). Although the binding is well documented, the 
low affinities, Kd ~800 µM could not consider as a potent drug candidate. Despite 
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that, the discovery of the binding pocket between CAP-1 and HIV-1 CA p24 has 
facilitated in identification of other potent compounds as mentioned below 
1.5.2(a)(ii) Acylhydrazone (14i and 14l) 
The binding pocket between CAP-1 and HIV-1 CA p24 was used by Tien and group 
to evaluated the binding of the molecules in series of acylhydrazone derivative. The 
molecules bind to NTD of HIV-1 CA p24 as well as CAP-1 but with two additional 
grooves of the protein. High-throughput in vitro CA p24 assembly showed two 
molecules (14i and 14l) significantly decreased the rate of p24 assembly in a dose-
dependent manner. These two molecules contain an L-phenylalanine side chain that 
demonstrated to inhibit 50% of SIV virus replication in CEM cells with low effective 
dose (Tian et al. 2009). Further modification of the side chain by replacing with L-
histidine exhibited significant anti-SIV activity, but the EC50 were still not as good as 
previously reported molecules (Jin et al. 2010). 
1.5.2(a)(iii) Quinolinone and phenyl (6 and 50) 
As mentioned above, CAP-1 and acylhydrazone derivative bind to the hydrophobic 
cavity of NTD of the HIV-1 CA p24. Small molecule inhibitors identified using the 
binding pocket between CA-1 and HIV-1 CA p24 could bind to the hydrophobic 
cavity of carboxyl-terminal domain (CTD) of the HIV-1 CA p24 at residue 165-215. 
Two potent compounds known as quinolinone and phenyl (6 and 50) inhibited the 
formation of the mature-like particle but not for the immature-like particle suggesting 
that the compound target CA instead of CANC. Unlike CAP-1, which do not affect 
the virus particle production, both quinolinone derivative (6) and phenyl derivative 
(50) decreased the HIV-1 particle release of different HIV-1 subtype B viruses and 
RT- or protease-resistant strains from compound-treated -MT-2 and -PBMC cells. 
Infectivity assay using normalised p24-virus infected MT-2 cells showed about 40% 
